Ocular system with anchoring implant and therapeutic agent

• US 10,406,029 B2
• Filed: 10/12/2015
• Issued: 09/10/2019
• Est. Priority Date: 04/07/2001
• Status: Active Grant

• Current Assignee: Glaukos Corporation
• Original Assignee: Glaukos Corporation
• Inventors: Tu, Hosheng, Artof, Jason, Haffner, David Steven, Smedley, Gregory T., Niksch, Barbara A.
• Primary Examiner(s): Deak, Leslie R
• Application Number:
  US14/881,100
• Publication Number:
  US 20160100983A1
• Time in Patent Office: 1,429 Days
• CPC Class Codes: A61F 2220/0008 Fixation appliances for connecting prostheses to the body
• CPC Class Codes: A61F 2230/0069 cylindrical
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61K 31/215 of carboxylic acids

Abstract

Ocular implants, delivery devices and methods for treating ocular disorders are disclosed. One method involves inserting an implant on one side of an eye. The implant has an anchor on a distal end portion and an outlet opening that is disposed proximal of the anchor. The implant is advanced across the eye to the other side of the eye. The anchor is inserted into eye tissue on the other side of the eye. A therapeutic agent is eluted using the implant.

Claims

1. An implant for treating an ocular disorder, the implant comprising:

a seat comprising a generally elongate tubular member having a proximal portion and a distal portion, configured to be positioned in an anterior chamber of an eye;

a therapeutic drug to be eluted from the implant; and

a base portion comprising a shank and an anchor having a sharp end, wherein the anchor is attached to a distal portion of the seat through the shank, the anchor disposed at a distal-most portion of the base portion and being adapted to penetrate only partially into a sclera of the eye and secure the implant in the eye, wherein the anchor is solid;

wherein a cross-sectional area of the shank is smaller than a cross-sectional area of the seat;

wherein at least a portion of the shank is dimensioned to reside in Schlemm'"'"'s canal.

2. The implant of claim 1 wherein a cross-sectional area of the base portion is smaller than a cross-sectional area of the seat.

3. The implant of claim 1 wherein at least a portion of the base portion is shaped and sized to be received in Schlemm'"'"'s canal of the eye.

4. The implant of claim 1 wherein the therapeutic agent is an anti-glaucoma drug.

5. The implant of claim 1 wherein the seat comprises a bottom surface adapted to rest against a trabecular meshwork of an eye.

6. The implant of claim 5 wherein the bottom surface of seat comprises a textured surface.

7. The implant of claim 1 further comprising an inlet opening in the proximal portion.

8. The implant of claim 7 wherein the implant further comprises an outlet in fluid communication with the inlet opening.

9. The implant of claim 8 wherein the outlet is disposed proximal of the anchor.

10. The implant of claim 1 wherein the implant further comprises a standoff disposed to space the outlet from a wall of Schlemm'"'"'s canal.

11. The implant of claim 1 wherein the anchor comprises a conical shape or a screw.

12. The implant of claim 1 wherein the tubular member is solid-walled.